Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NYSE | Common Stock
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through two segments, Commercial Operations and Total R&D.
The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | 1.29 Increased by +0.78% | 1.23 Increased by +4.88% |
| Jul 31, 24 | 1.10 Increased by +13.40% | 0.99 Increased by +11.11% |
| May 1, 24 | 1.09 Increased by +21.11% | 0.91 Increased by +19.78% |
| Jan 31, 24 | 0.72 Increased by +18.03% | 0.76 Decreased by -5.26% |
| Nov 1, 23 | 1.28 Increased by +16.36% | 1.14 Increased by +12.28% |
| Jul 26, 23 | 0.97 Increased by +11.49% | 0.87 Increased by +11.49% |
| Apr 26, 23 | 0.90 Decreased by -17.43% | 0.82 Increased by +9.76% |
| Feb 1, 23 | 0.61 Decreased by -29.07% | 0.50 Increased by +22.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 8.01 B Decreased by -0.50% | -58.00 M Decreased by -116.57% | Decreased by -0.72% Decreased by -116.65% |
| Jun 30, 24 | 8.01 B Decreased by -1.66% | -58.00 M Decreased by -103.96% | Decreased by -0.72% Decreased by -104.03% |
| Mar 31, 24 | 7.88 B Increased by +13.42% | 1.17 B Decreased by -21.28% | Increased by +14.88% Decreased by -30.59% |
| Dec 31, 23 | 7.36 B Decreased by -0.18% | 1.05 B Decreased by -28.41% | Increased by +14.21% Decreased by -28.28% |
| Sep 30, 23 | 8.05 B Increased by +2.85% | 350.00 M Decreased by -55.07% | Increased by +4.35% Decreased by -56.31% |
| Jun 30, 23 | 8.15 B Increased by +17.58% | 1.46 B Increased by +74.70% | Increased by +17.97% Increased by +48.58% |
| Mar 31, 23 | 6.95 B Decreased by -28.93% | 1.49 B Decreased by -17.31% | Increased by +21.44% Increased by +16.34% |
| Dec 31, 22 | 7.38 B Decreased by -22.58% | 1.46 B Increased by +95.06% | Increased by +19.81% Increased by +151.94% |